[go: up one dir, main page]

MA34727B1 - Imidazolylimidazoles condensés utilisés comme composés antiviraux - Google Patents

Imidazolylimidazoles condensés utilisés comme composés antiviraux

Info

Publication number
MA34727B1
MA34727B1 MA36000A MA36000A MA34727B1 MA 34727 B1 MA34727 B1 MA 34727B1 MA 36000 A MA36000 A MA 36000A MA 36000 A MA36000 A MA 36000A MA 34727 B1 MA34727 B1 MA 34727B1
Authority
MA
Morocco
Prior art keywords
antiviral compounds
compounds
imidazolylimidazoles
condensed
condensed imidazolylimidazoles
Prior art date
Application number
MA36000A
Other languages
English (en)
Inventor
Elizabeth M Bacon
Jeromy J Cottell
Ashley Anne Katana
Darryl Kato
Evan S Krygowski
John O Link
James Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Zheng-Yu Yang
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA34727B1 publication Critical patent/MA34727B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention a pour objets des composés antiviraux, des compositions pharmaceutiques contenant de tels composés, des méthodes thérapeutiques comprenant l'administration de tels composés et des procédés et des intermédiaires utiles à la préparation de tels composés.
MA36000A 2011-11-16 2013-06-10 Imidazolylimidazoles condensés utilisés comme composés antiviraux MA34727B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161560654P 2011-11-16 2011-11-16
PCT/US2012/065681 WO2013075029A1 (fr) 2011-11-16 2012-11-16 Imidazolylimidazoles condensés utilisés comme composés antiviraux

Publications (1)

Publication Number Publication Date
MA34727B1 true MA34727B1 (fr) 2013-12-03

Family

ID=47324426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36000A MA34727B1 (fr) 2011-11-16 2013-06-10 Imidazolylimidazoles condensés utilisés comme composés antiviraux

Country Status (36)

Country Link
US (14) US8940718B2 (fr)
EP (4) EP3431477B1 (fr)
JP (5) JP6082749B2 (fr)
KR (5) KR20190121406A (fr)
CN (2) CN105837584B (fr)
AP (1) AP2013006877A0 (fr)
AU (1) AU2012318253B8 (fr)
BR (1) BR112013012091A2 (fr)
CA (2) CA2884712A1 (fr)
CL (1) CL2013001428A1 (fr)
CO (1) CO6791562A2 (fr)
CR (1) CR20130231A (fr)
CY (2) CY1116987T1 (fr)
DK (2) DK2635588T3 (fr)
EA (4) EA037883B1 (fr)
EC (2) ECSP13012790A (fr)
ES (3) ES2687291T3 (fr)
HR (2) HRP20150725T1 (fr)
HU (2) HUE039966T2 (fr)
IL (5) IL226345A (fr)
LT (1) LT2907816T (fr)
MA (1) MA34727B1 (fr)
MD (2) MD4403C1 (fr)
ME (1) ME02196B (fr)
MX (4) MX346729B (fr)
MY (2) MY173045A (fr)
PE (2) PE20171444A1 (fr)
PH (2) PH12013500976A1 (fr)
PL (3) PL2635588T3 (fr)
PT (3) PT2907816T (fr)
RS (2) RS54207B1 (fr)
SG (1) SG10201700947UA (fr)
SI (3) SI3431477T1 (fr)
SM (2) SMT201800470T1 (fr)
UA (2) UA119437C2 (fr)
WO (1) WO2013075029A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604620T5 (pl) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
MX360800B (es) 2009-05-13 2018-11-16 Gilead Pharmasset Llc Star Compuestos antivirales.
TWI640526B (zh) 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
TWI482766B (zh) 2011-07-09 2015-05-01 Sunshine Lake Pharma Co Ltd As a spiro compound for hepatitis C virus inhibitors
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
DK2635588T3 (en) 2011-11-16 2015-09-07 Gilead Pharmasset Llc Dehydrated imidazolylimidazoler as anti-viral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10032995B2 (en) 2013-02-07 2018-07-24 Kyulux, Inc. Compound having diazatriphenylene ring structure, and organic electroluminescent device
WO2014185995A1 (fr) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Traitements de l'hépatite c avec du sofosbuvir
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20160158200A1 (en) * 2013-07-09 2016-06-09 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
EP3038601B1 (fr) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Préparation combinée de deux composés antiviraux
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
JP6568541B2 (ja) 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
CN106008552B (zh) * 2015-03-01 2020-08-21 南京圣和药业股份有限公司 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017060820A1 (fr) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Procédé de préparation de velpatasvir
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
CN105801553B (zh) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 一种苯并色烯衍生物的制备方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017184670A2 (fr) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Méthodes de traitement d'infections à virus zika
EP3452038B1 (fr) * 2016-05-05 2022-07-06 Laurus Labs Limited Procédé de préparation d'intermédiaires utiles dans la préparation d'inhibiteurs du virus de l'hépatite c (vhc)
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4483875A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
AU2017271990B2 (en) 2016-05-27 2019-12-19 Gilead Sciences, Inc. Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN107573380B (zh) * 2016-11-30 2020-06-02 上海博志研新药物技术有限公司 维帕他韦中间体、制备方法及应用
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CN107655986B (zh) * 2017-09-08 2020-11-03 安徽一灵药业有限公司 一种维帕他韦有关物质的检测方法
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
CN108276421B (zh) * 2018-02-13 2019-08-06 浙江永太药业有限公司 一种维帕他韦的合成方法
AU2020366731A1 (en) 2019-10-18 2022-04-21 Wockhardt Limited Nitrogen containing bicyclic compounds
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN110981879B (zh) * 2019-12-09 2021-03-05 南通常佑药业科技有限公司 一种制备ns5a抑制剂-维帕他韦的方法
CN113072615B (zh) * 2021-03-24 2023-01-10 上海法默生物科技有限公司 一种维帕他韦中间体的制备方法
WO2022246109A1 (fr) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Dérivés pentacycliques en tant qu'inhibiteurs du virus zika
JP7723119B2 (ja) 2021-05-21 2025-08-13 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス感染症の治療のための四環系化合物
EP4355319A4 (fr) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. Polythérapie anti-vhc avantageuse

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (fr) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
EP1411928A1 (fr) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2004099241A1 (fr) 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Poche de liaison de l'inhibiteur de la polymerase ns5b du virus de l'hepatite c
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
AP2461A (en) 2004-07-16 2012-09-14 Gilead Sciences Inc Antiviral compounds
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2100606A4 (fr) 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd Préparation revêtue d'un film ayant une stabilité améliorée
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102621A2 (fr) * 2008-02-11 2009-08-20 Qualcomm Mems Technologies, Inc. Procédés de mesure et de caractérisation de modulateurs interférométriques
WO2009102318A1 (fr) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0822323A2 (pt) 2008-02-13 2015-06-16 Bristol Myers Squibb Co Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
WO2010096777A1 (fr) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibiteurs du ns5a du vhc
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
CA2756255A1 (fr) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Inhibiteurs bicycliques du vhc substitues
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
MX360800B (es) * 2009-05-13 2018-11-16 Gilead Pharmasset Llc Star Compuestos antivirales.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
EP2475256A4 (fr) 2009-09-11 2013-06-05 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
WO2011087740A1 (fr) * 2009-12-22 2011-07-21 Schering Corporation Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
EP2545060B1 (fr) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Composés de silyle tricycliques fusionnés et leurs procédés d'utilisation pour le traitement de maladies virales
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2616461A4 (fr) 2010-08-26 2014-03-26 Rfs Pharma Llc Inhibiteurs puissants et sélectifs du virus de l'hépatite c
WO2012048421A1 (fr) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
TWI640526B (zh) * 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
WO2012087976A2 (fr) 2010-12-21 2012-06-28 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
DK2635588T3 (en) 2011-11-16 2015-09-07 Gilead Pharmasset Llc Dehydrated imidazolylimidazoler as anti-viral compounds
HK1201186A1 (en) 2011-12-29 2015-08-28 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
EP3038601B1 (fr) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Préparation combinée de deux composés antiviraux
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Also Published As

Publication number Publication date
AU2012318253A1 (en) 2013-05-30
PE20141163A1 (es) 2014-09-21
US8575135B2 (en) 2013-11-05
EA030941B1 (ru) 2018-10-31
EP2635588A1 (fr) 2013-09-11
MD4403C1 (ro) 2016-09-30
NZ752834A (en) 2021-01-29
IL244122A0 (en) 2016-04-21
HRP20150725T1 (hr) 2015-08-14
ES2544107T3 (es) 2015-08-27
EA202190619A1 (ru) 2021-09-30
EA201890333A1 (ru) 2018-10-31
US20190276468A1 (en) 2019-09-12
ECSP18048718A (es) 2018-07-31
NZ720856A (en) 2017-12-22
PL2907816T3 (pl) 2019-03-29
HRP20181384T1 (hr) 2018-12-28
US9868745B2 (en) 2018-01-16
US20140309432A1 (en) 2014-10-16
NZ737924A (en) 2019-06-28
IL226345A0 (en) 2013-07-31
US20200071337A1 (en) 2020-03-05
PE20171444A1 (es) 2017-09-29
MD20130029A2 (en) 2013-09-30
SMT201500197B (it) 2015-09-07
AP2013006877A0 (en) 2013-05-31
EP2907816B1 (fr) 2018-06-13
MX2020010330A (es) 2020-10-22
SG10201700947UA (en) 2017-03-30
CL2013001428A1 (es) 2014-06-27
RS57638B1 (sr) 2018-11-30
JP2016199593A (ja) 2016-12-01
EA201591244A1 (ru) 2016-02-29
MX377552B (es) 2025-03-10
US9221833B2 (en) 2015-12-29
DK2907816T3 (en) 2018-09-24
EP2907816A1 (fr) 2015-08-19
ES2687291T3 (es) 2018-10-24
IL244124A0 (en) 2016-04-21
US9051340B2 (en) 2015-06-09
KR20200117043A (ko) 2020-10-13
CA2815082A1 (fr) 2013-05-23
CR20130231A (es) 2013-09-19
MX2013005575A (es) 2013-09-05
EP3431477B1 (fr) 2020-10-14
MD4403B1 (ro) 2016-02-29
NZ610525A (en) 2017-05-26
PH12013500976A1 (en) 2016-10-26
KR102241651B1 (ko) 2021-04-20
US20130156732A1 (en) 2013-06-20
CY1116987T1 (el) 2017-04-05
IL252345A0 (en) 2017-07-31
AU2012318253A8 (en) 2015-08-13
CN103328480A (zh) 2013-09-25
EP2635588B1 (fr) 2015-06-10
US20150141326A1 (en) 2015-05-21
JP2018024705A (ja) 2018-02-15
US20130164260A1 (en) 2013-06-27
BR112013012091A2 (pt) 2019-09-10
MY173045A (en) 2019-12-20
SI2907816T1 (sl) 2018-10-30
WO2013075029A1 (fr) 2013-05-23
ME02196B (fr) 2016-02-20
IL252345B (en) 2022-01-01
CO6791562A2 (es) 2013-11-14
SI2635588T1 (sl) 2015-10-30
RS54207B1 (sr) 2015-12-31
KR20190121406A (ko) 2019-10-25
ES2843023T3 (es) 2021-07-15
US20180244683A1 (en) 2018-08-30
PH12015502839B1 (en) 2020-10-30
PT2635588E (pt) 2015-09-14
IL226345A (en) 2016-03-31
US20130177530A1 (en) 2013-07-11
US20160083394A1 (en) 2016-03-24
CY1121225T1 (el) 2020-05-29
AU2012318253B2 (en) 2015-08-06
UA110354C2 (uk) 2015-12-25
EA023644B1 (ru) 2016-06-30
MX361735B (es) 2018-12-14
MX346729B (es) 2017-03-30
US20140112885A1 (en) 2014-04-24
SMT201800470T1 (it) 2018-11-09
PT2907816T (pt) 2018-10-18
JP6082749B2 (ja) 2017-02-15
PL3431477T3 (pl) 2021-04-06
UA119437C2 (uk) 2019-06-25
HUE039966T2 (hu) 2019-02-28
KR20180095119A (ko) 2018-08-24
HUE027733T2 (en) 2016-10-28
SI3431477T1 (sl) 2021-01-29
MD4521B1 (ro) 2017-10-31
PH12015502839A1 (en) 2019-05-15
HK1188989A1 (en) 2014-05-23
US8921341B2 (en) 2014-12-30
EP3431477A1 (fr) 2019-01-23
KR101890400B1 (ko) 2018-08-21
EA201390576A1 (ru) 2013-11-29
IL244123A0 (en) 2016-04-21
JP2015512860A (ja) 2015-04-30
US9809600B2 (en) 2017-11-07
CN105837584B (zh) 2018-07-13
EA037883B1 (ru) 2021-05-31
EP3778606A2 (fr) 2021-02-17
KR20210043734A (ko) 2021-04-21
CN103328480B (zh) 2016-05-25
DK2635588T3 (en) 2015-09-07
KR102036469B1 (ko) 2019-10-24
MY201670A (en) 2024-03-12
CA2815082C (fr) 2015-07-07
MD20150091A2 (ro) 2016-02-29
CA2884712A1 (fr) 2013-05-23
KR20140096239A (ko) 2014-08-05
LT2907816T (lt) 2018-09-10
JP2021001230A (ja) 2021-01-07
US10807990B2 (en) 2020-10-20
EP3778606A3 (fr) 2021-03-03
PL2635588T3 (pl) 2015-10-30
US8940718B2 (en) 2015-01-27
AU2012318253B8 (en) 2015-08-13
US20180186806A1 (en) 2018-07-05
MD4521C1 (ro) 2018-05-31
US20150299213A1 (en) 2015-10-22
US20170145027A1 (en) 2017-05-25
US20210053981A1 (en) 2021-02-25
PT3431477T (pt) 2020-12-15
JP2019206597A (ja) 2019-12-05
ECSP13012790A (es) 2013-10-31
CN105837584A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MD4496B1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
MA34474B1 (fr) Agonistes de gpr40
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MX2012007410A (es) Compuestos antivirales novedosos.
MA38138A1 (fr) Dérivés inédits de quinolone
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
GB2511685A (en) Muscarinic m1 receptor agonists
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34308B1 (fr) Triazolopyridines substituées
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione